NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis $1.47 +0.02 (+1.38%) Closing price 04:00 PM EasternExtended Trading$1.47 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Marker Therapeutics Stock (NASDAQ:MRKR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Marker Therapeutics alerts:Sign Up Key Stats Today's Range$1.44▼$1.5050-Day Range$1.24▼$1.7552-Week Range$0.81▼$4.07Volume65,844 shsAverage Volume57,533 shsMarket Capitalization$24.50 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Marker Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies. Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers. The company has initiated early-phase clinical studies in patients with HPV16-positive head and neck cancers, as well as exploratory trials in other solid tumor indications. Marker conducts its research and development activities at its headquarters in Houston, Texas, and collaborates with academic and clinical partners across the United States to support trial enrollment and translational research efforts. Founded in 2019 through a corporate reorganization and public listing, Marker Therapeutics transitioned its focus from earlier-stage RNA-based programs to cell-based immunotherapies. The company is guided by a management team experienced in cell therapy development, process scale-up and regulatory strategy. With an emphasis on personalized medicine, Marker is advancing its pipeline toward later-stage studies and exploring combination approaches alongside established oncology agents.AI Generated. May Contain Errors. Read More Marker Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreMRKR MarketRank™: Marker Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 649th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingMarker Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMarker Therapeutics has a consensus price target of $10.00, representing about 580.3% upside from its current price of $1.47.Amount of Analyst CoverageMarker Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Marker Therapeutics are expected to decrease in the coming year, from ($1.17) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marker Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marker Therapeutics is -2.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Marker Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.56% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 3.78, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently increased by 62.70%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. News and Social Media3.7 / 5News SentimentN/A News SentimentMarker Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Marker Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for MRKR on MarketBeat in the last 30 days. MarketBeat Follows5 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.70% of the stock of Marker Therapeutics is held by insiders.Percentage Held by Institutions22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRKR Stock News HeadlinesMarker Therapeutics (NASDAQ:MRKR) and Indivior (NASDAQ:INDV) Head to Head SurveyMay 29, 2026 | americanbankingnews.comMarker Therapeutics Sets Date for 2026 Annual MeetingMay 19, 2026 | theglobeandmail.comTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate of an entire generation. According to Porter Stansberry, founder of one of the largest independent financial research firms in the world, it is happening again. Fortune calls it 'the biggest change to the world's relationship with the dollar' in a generation. Stansberry says Trump's money reset - enacted through executive orders and a treaty signed by 13 nations in December 2025 called Pax Silica - could determine whether you are enriched or quietly impoverished by the shift already underway.June 4 at 1:00 AM | Porter & Company (Ad)Marker Therapeutics (MRKR) price target decreased by 12.83% to 8.02April 9, 2026 | msn.comMarker Therapeutics Reports Encouraging Phase 1 APOLLO Data and Corporate Developments in Immuno-OncologyMarch 18, 2026 | quiverquant.comQMarker Therapeutics Reports Year-End 2025 Corporate and Financial ResultsMarch 18, 2026 | globenewswire.comMarker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFebruary 18, 2026 | globenewswire.comGood Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell TechnologyJanuary 26, 2026 | markets.businessinsider.comSee More Headlines MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed this year? Marker Therapeutics' stock was trading at $1.49 at the start of the year. Since then, MRKR stock has decreased by 1.3% and is now trading at $1.47. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) announced its quarterly earnings results on Friday, May, 15th. The company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02. The firm earned $0.75 million during the quarter, compared to analysts' expectations of $0.78 million. Marker Therapeutics had a negative trailing twelve-month return on equity of 73.29% and a negative net margin of 343.03%. Who are Marker Therapeutics' major shareholders? Top institutional investors of Marker Therapeutics include Renaissance Technologies LLC (1.05%). View institutional ownership trends. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK). Company Calendar Last Earnings5/15/2026Today6/04/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 MRKR's financial health is in the Green zone, according to TradeSmith. MRKR has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRKR CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees60Year Founded2018Price Target and Rating Average Price Target for Marker Therapeutics$10.00 High Price Target$10.00 Low Price Target$10.00 Potential Upside/Downside+580.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.16 million Net Margins-343.03% Pretax Margin-341.32% Return on Equity-73.29% Return on Assets-59.70% Debt Debt-to-Equity RatioN/A Current Ratio4.79 Quick Ratio4.79 Sales & Book Value Annual Sales$3.55 million Price / Sales6.90 Cash FlowN/A Price / Cash FlowN/A Book Value$1.01 per share Price / Book1.46Miscellaneous Outstanding Shares16,670,000Free Float15,723,000Market Cap$24.50 million OptionableNot Optionable Beta1.44 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:MRKR) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersDo NOT Buy SpaceX – Do This InsteadSpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...Stansberry Research | SponsoredTrump named it. Scientists built it. Here's what it means for you.President Trump's team is calling it 'Golden Dawn' - America's new Manhattan Project, but for AI. Spanning mor...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredGiving “2022 pre-ChatGPT” vibes (but 10x bigger)When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...StocksToTrade | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
